Skip to main content

A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension

Active, not recruiting · Phase 4 · NCT05203510

Conditions: Pulmonary Arterial Hypertension

At a glance

Research payments reported, 2025
$2.1M
U.S. investigators named
29
Sites paid
27
Planned or actual enrollment
52

About the trial

Sponsor
United Therapeutics (with Lung Biotechnology PBC)
Tested
Parenteral Treprostinil (drug), Oral Treprostinil (drug)
Dates
Started 2022-10-20; completion 2028-04-30
Results posted
Not yet

The primary objective of this study is to assess the effect of early and rapid treprostinil therapy for mean pulmonary artery pressure (mPAP) reduction to improve right ventricular (RV) function and reverse RV remodeling in participants with pulmonary arterial hypertension (PAH).

From ClinicalTrials.gov, last updated 2025-12-09. Full record, eligibility and contacts (opens in a new tab)

Industry funding

United Therapeutics Corporation reported $2.1M in research payments for this study in 2025 (442 payments).

Products named: Remodulin

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.